Modality
Fusion Protein
MOA
CDK2i
Target
PARP
Pathway
RNA Splicing
PAHACCPV
Development Pipeline
Preclinical
~Nov 2013
→ ~Feb 2015
Phase 1
~May 2015
→ ~Aug 2016
Phase 2
~Nov 2016
→ ~Feb 2018
Phase 3
May 2018
→ Dec 2029
Phase 3Current
NCT06977993
580 pts·PAH
2021-04→2025-08·Recruiting
NCT05375584
295 pts·ACC
2025-01→2029-12·Recruiting
NCT05892380
2,898 pts·PAH
2018-05→2025-06·Not yet recruiting
3,773 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-06-0410mo agoPh3 Readout· PAH
2025-08-227mo agoPh3 Readout· PAH
2029-12-033.7y awayPh3 Readout· ACC
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Not yet…
P3
Recruit…
P3
Recruit…
Catalysts
Ph3 Readout
2025-06-04 · 10mo ago
PAH
Ph3 Readout
2025-08-22 · 7mo ago
PAH
Ph3 Readout
2029-12-03 · 3.7y away
ACC
RecruitingNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06977993 | Phase 3 | PAH | Recruiting | 580 | CR |
| NCT05375584 | Phase 3 | ACC | Recruiting | 295 | UPDRS |
| NCT05892380 | Phase 3 | PAH | Not yet recr... | 2898 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |